Primary Chylomicronemia in Patients with Severe Familial Hypertriglyceridemia Responds to Long-Term Treatment with (n-3) Fatty Acids
Because it disturbs microcirculation, chylomicronemia can cause severe clinical complications such as acute pancreatitis. Dietary measures are very important in the prevention and treatment of this condition. Dietary supplementation with (n-3) fatty acids has been shown to be of benefit in short-ter...
Gespeichert in:
Veröffentlicht in: | The Journal of nutrition 1995-06, Vol.125 (6), p.1490-1494 |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1494 |
---|---|
container_issue | 6 |
container_start_page | 1490 |
container_title | The Journal of nutrition |
container_volume | 125 |
creator | Pschierer, Volkhard Richter, Werner O. Schwandt, Peter |
description | Because it disturbs microcirculation, chylomicronemia can cause severe clinical complications such as acute pancreatitis. Dietary measures are very important in the prevention and treatment of this condition. Dietary supplementation with (n-3) fatty acids has been shown to be of benefit in short-term treatment of chylomicronemia. To evaluate the long-term efficacy of (n-3) fatty acids we added 2.16 or 4.32 g/d (for 3 mo) and 3.24 g/d (for a further 8 mo after 1 mo of no treatment (n-3) fatty acids to the diet of eight patients with primary chylomicronemia. Serum triglycerides decreased significantly from 15.0 ± 2.5 to 9.9 ± 2.8 mmol/L (P < 0.01) after 11 mo of treatment, and VLDL triglycerides decreased from 12.3 ± 2.8 to 9.0 ± 2.4 mmol/L (P < 0.01), resulting in a significant decrease of plasma viscosity from 1.56 ± 0.17 mPa·s to 1.47 ± 0.12 mPa·s (P < 0.01). Total cholesterol, HDL and LDL cholesterol as well as lipoprotein (a) and fibrinogen concentrations were not affected by fish oil treatment. The presence of chylomicrons and chylomicron remnants (apolipoprotein B 48 concentration in the lipoprotein fraction with a density lower than 1.006 kg/L) was significantly reduced from 4.82 ± 1.08 to 1.06 ± 0.38 mg/L (P < 0.01). Body weight increased significantly from 71.0 ± 4.6 kg to 75.2 ± 5.3 kg after 11 mo of treatment with (n-3) fatty acids. These data indicate that despite an increase in body weight, long-term supplementation of a diet with (n-3) fatty acids results in a persistent decrease of serum triglyceride concentrations, a pronounced reduction in the number of chylomicrons present in the fasting state, and an improvement in plasma viscosity. |
doi_str_mv | 10.1093/jn/125.6.1490 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_77339927</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0022316623035617</els_id><sourcerecordid>1866389</sourcerecordid><originalsourceid>FETCH-LOGICAL-e310t-6bb3e6edf196c70fb5f4d0d0d5f2c7e0fe6042858d160ac2f0ce529dcd02af0c3</originalsourceid><addsrcrecordid>eNpdkcFrFDEUxoModVs9ehSCiOhhti_JTLI5lsVaYcGi6zlkkzdtlpnMmmQre_cPb-ouHuQdwuP75SP5PkLeMJgz0OJyGy8Z7-ZyzloNz8iMdS1rJAN4TmYAnDeCSfmSnOe8BYAKLc7ImVILroHPyJ_bFEabDnR5fximMbg0RRyDpSHSW1sCxpLp71Du6Q98wIT02o5hCHagN4cdppLC3XBwmIL_e-s75t0UfaZloqsp3jVrTCNdJ7RlrFZHp4-xEZ-qUSkHeuWCz6_Ii94OGV-fzgvy8_rzennTrL59-bq8WjUoGJRGbjYCJfqeaekU9Juubz3U6XruFEKPElq-6BaeSbCO9-Cw49o7D9zWRVyQD0ffXZp-7TEXM4bscBhsxGmfjVJCaM1VBd_9B26nfYr1bYZp1QquJVTo7Qnab0b0ZndM0pyyrfr7k26zs0OfbHQh_8NEp3TbioqpI4b15w8Bk8muxu7Qh4SuGD8Fw8A8dW220dSujTRPXYtHC3mb9w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>197432960</pqid></control><display><type>article</type><title>Primary Chylomicronemia in Patients with Severe Familial Hypertriglyceridemia Responds to Long-Term Treatment with (n-3) Fatty Acids</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Pschierer, Volkhard ; Richter, Werner O. ; Schwandt, Peter</creator><creatorcontrib>Pschierer, Volkhard ; Richter, Werner O. ; Schwandt, Peter</creatorcontrib><description>Because it disturbs microcirculation, chylomicronemia can cause severe clinical complications such as acute pancreatitis. Dietary measures are very important in the prevention and treatment of this condition. Dietary supplementation with (n-3) fatty acids has been shown to be of benefit in short-term treatment of chylomicronemia. To evaluate the long-term efficacy of (n-3) fatty acids we added 2.16 or 4.32 g/d (for 3 mo) and 3.24 g/d (for a further 8 mo after 1 mo of no treatment (n-3) fatty acids to the diet of eight patients with primary chylomicronemia. Serum triglycerides decreased significantly from 15.0 ± 2.5 to 9.9 ± 2.8 mmol/L (P < 0.01) after 11 mo of treatment, and VLDL triglycerides decreased from 12.3 ± 2.8 to 9.0 ± 2.4 mmol/L (P < 0.01), resulting in a significant decrease of plasma viscosity from 1.56 ± 0.17 mPa·s to 1.47 ± 0.12 mPa·s (P < 0.01). Total cholesterol, HDL and LDL cholesterol as well as lipoprotein (a) and fibrinogen concentrations were not affected by fish oil treatment. The presence of chylomicrons and chylomicron remnants (apolipoprotein B 48 concentration in the lipoprotein fraction with a density lower than 1.006 kg/L) was significantly reduced from 4.82 ± 1.08 to 1.06 ± 0.38 mg/L (P < 0.01). Body weight increased significantly from 71.0 ± 4.6 kg to 75.2 ± 5.3 kg after 11 mo of treatment with (n-3) fatty acids. These data indicate that despite an increase in body weight, long-term supplementation of a diet with (n-3) fatty acids results in a persistent decrease of serum triglyceride concentrations, a pronounced reduction in the number of chylomicrons present in the fasting state, and an improvement in plasma viscosity.</description><identifier>ISSN: 0022-3166</identifier><identifier>EISSN: 1541-6100</identifier><identifier>DOI: 10.1093/jn/125.6.1490</identifier><identifier>PMID: 7782902</identifier><identifier>CODEN: JONUAI</identifier><language>eng</language><publisher>Bethesda, MD: Elsevier Inc</publisher><subject>(n-3) fatty acids ; Adult ; Aged ; Biological and medical sciences ; Body Weight - drug effects ; Body Weight - physiology ; Cholesterol - blood ; Chylomicrons - blood ; Diet ; Dose-Response Relationship, Drug ; Errors of metabolism ; Fatty Acids, Omega-3 - administration & dosage ; Fatty Acids, Omega-3 - pharmacology ; Fatty Acids, Omega-3 - therapeutic use ; Female ; Fibrinogen - analysis ; Food, Fortified ; General and cellular metabolism. Vitamins ; Humans ; Hyperlipoproteinemia Type IV - blood ; Hyperlipoproteinemia Type IV - drug therapy ; hypertriglyceridemia ; Lipids (lysosomal enzyme disorders, storage diseases) ; Lipids - blood ; Lipoproteins - blood ; Male ; Medical disorders ; Medical sciences ; Metabolic diseases ; Middle Aged ; Oils & fats ; Pharmacology. Drug treatments ; plasma viscosity ; primary chylomicronemia ; Triglycerides - blood</subject><ispartof>The Journal of nutrition, 1995-06, Vol.125 (6), p.1490-1494</ispartof><rights>1995 American Society for Nutrition.</rights><rights>1995 INIST-CNRS</rights><rights>Copyright American Institute of Nutrition Jun 1995</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=3579443$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/7782902$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pschierer, Volkhard</creatorcontrib><creatorcontrib>Richter, Werner O.</creatorcontrib><creatorcontrib>Schwandt, Peter</creatorcontrib><title>Primary Chylomicronemia in Patients with Severe Familial Hypertriglyceridemia Responds to Long-Term Treatment with (n-3) Fatty Acids</title><title>The Journal of nutrition</title><addtitle>J Nutr</addtitle><description>Because it disturbs microcirculation, chylomicronemia can cause severe clinical complications such as acute pancreatitis. Dietary measures are very important in the prevention and treatment of this condition. Dietary supplementation with (n-3) fatty acids has been shown to be of benefit in short-term treatment of chylomicronemia. To evaluate the long-term efficacy of (n-3) fatty acids we added 2.16 or 4.32 g/d (for 3 mo) and 3.24 g/d (for a further 8 mo after 1 mo of no treatment (n-3) fatty acids to the diet of eight patients with primary chylomicronemia. Serum triglycerides decreased significantly from 15.0 ± 2.5 to 9.9 ± 2.8 mmol/L (P < 0.01) after 11 mo of treatment, and VLDL triglycerides decreased from 12.3 ± 2.8 to 9.0 ± 2.4 mmol/L (P < 0.01), resulting in a significant decrease of plasma viscosity from 1.56 ± 0.17 mPa·s to 1.47 ± 0.12 mPa·s (P < 0.01). Total cholesterol, HDL and LDL cholesterol as well as lipoprotein (a) and fibrinogen concentrations were not affected by fish oil treatment. The presence of chylomicrons and chylomicron remnants (apolipoprotein B 48 concentration in the lipoprotein fraction with a density lower than 1.006 kg/L) was significantly reduced from 4.82 ± 1.08 to 1.06 ± 0.38 mg/L (P < 0.01). Body weight increased significantly from 71.0 ± 4.6 kg to 75.2 ± 5.3 kg after 11 mo of treatment with (n-3) fatty acids. These data indicate that despite an increase in body weight, long-term supplementation of a diet with (n-3) fatty acids results in a persistent decrease of serum triglyceride concentrations, a pronounced reduction in the number of chylomicrons present in the fasting state, and an improvement in plasma viscosity.</description><subject>(n-3) fatty acids</subject><subject>Adult</subject><subject>Aged</subject><subject>Biological and medical sciences</subject><subject>Body Weight - drug effects</subject><subject>Body Weight - physiology</subject><subject>Cholesterol - blood</subject><subject>Chylomicrons - blood</subject><subject>Diet</subject><subject>Dose-Response Relationship, Drug</subject><subject>Errors of metabolism</subject><subject>Fatty Acids, Omega-3 - administration & dosage</subject><subject>Fatty Acids, Omega-3 - pharmacology</subject><subject>Fatty Acids, Omega-3 - therapeutic use</subject><subject>Female</subject><subject>Fibrinogen - analysis</subject><subject>Food, Fortified</subject><subject>General and cellular metabolism. Vitamins</subject><subject>Humans</subject><subject>Hyperlipoproteinemia Type IV - blood</subject><subject>Hyperlipoproteinemia Type IV - drug therapy</subject><subject>hypertriglyceridemia</subject><subject>Lipids (lysosomal enzyme disorders, storage diseases)</subject><subject>Lipids - blood</subject><subject>Lipoproteins - blood</subject><subject>Male</subject><subject>Medical disorders</subject><subject>Medical sciences</subject><subject>Metabolic diseases</subject><subject>Middle Aged</subject><subject>Oils & fats</subject><subject>Pharmacology. Drug treatments</subject><subject>plasma viscosity</subject><subject>primary chylomicronemia</subject><subject>Triglycerides - blood</subject><issn>0022-3166</issn><issn>1541-6100</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1995</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkcFrFDEUxoModVs9ehSCiOhhti_JTLI5lsVaYcGi6zlkkzdtlpnMmmQre_cPb-ouHuQdwuP75SP5PkLeMJgz0OJyGy8Z7-ZyzloNz8iMdS1rJAN4TmYAnDeCSfmSnOe8BYAKLc7ImVILroHPyJ_bFEabDnR5fximMbg0RRyDpSHSW1sCxpLp71Du6Q98wIT02o5hCHagN4cdppLC3XBwmIL_e-s75t0UfaZloqsp3jVrTCNdJ7RlrFZHp4-xEZ-qUSkHeuWCz6_Ii94OGV-fzgvy8_rzennTrL59-bq8WjUoGJRGbjYCJfqeaekU9Juubz3U6XruFEKPElq-6BaeSbCO9-Cw49o7D9zWRVyQD0ffXZp-7TEXM4bscBhsxGmfjVJCaM1VBd_9B26nfYr1bYZp1QquJVTo7Qnab0b0ZndM0pyyrfr7k26zs0OfbHQh_8NEp3TbioqpI4b15w8Bk8muxu7Qh4SuGD8Fw8A8dW220dSujTRPXYtHC3mb9w</recordid><startdate>19950601</startdate><enddate>19950601</enddate><creator>Pschierer, Volkhard</creator><creator>Richter, Werner O.</creator><creator>Schwandt, Peter</creator><general>Elsevier Inc</general><general>American Society for Nutritional Sciences</general><general>American Institute of Nutrition</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope></search><sort><creationdate>19950601</creationdate><title>Primary Chylomicronemia in Patients with Severe Familial Hypertriglyceridemia Responds to Long-Term Treatment with (n-3) Fatty Acids</title><author>Pschierer, Volkhard ; Richter, Werner O. ; Schwandt, Peter</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-e310t-6bb3e6edf196c70fb5f4d0d0d5f2c7e0fe6042858d160ac2f0ce529dcd02af0c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1995</creationdate><topic>(n-3) fatty acids</topic><topic>Adult</topic><topic>Aged</topic><topic>Biological and medical sciences</topic><topic>Body Weight - drug effects</topic><topic>Body Weight - physiology</topic><topic>Cholesterol - blood</topic><topic>Chylomicrons - blood</topic><topic>Diet</topic><topic>Dose-Response Relationship, Drug</topic><topic>Errors of metabolism</topic><topic>Fatty Acids, Omega-3 - administration & dosage</topic><topic>Fatty Acids, Omega-3 - pharmacology</topic><topic>Fatty Acids, Omega-3 - therapeutic use</topic><topic>Female</topic><topic>Fibrinogen - analysis</topic><topic>Food, Fortified</topic><topic>General and cellular metabolism. Vitamins</topic><topic>Humans</topic><topic>Hyperlipoproteinemia Type IV - blood</topic><topic>Hyperlipoproteinemia Type IV - drug therapy</topic><topic>hypertriglyceridemia</topic><topic>Lipids (lysosomal enzyme disorders, storage diseases)</topic><topic>Lipids - blood</topic><topic>Lipoproteins - blood</topic><topic>Male</topic><topic>Medical disorders</topic><topic>Medical sciences</topic><topic>Metabolic diseases</topic><topic>Middle Aged</topic><topic>Oils & fats</topic><topic>Pharmacology. Drug treatments</topic><topic>plasma viscosity</topic><topic>primary chylomicronemia</topic><topic>Triglycerides - blood</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pschierer, Volkhard</creatorcontrib><creatorcontrib>Richter, Werner O.</creatorcontrib><creatorcontrib>Schwandt, Peter</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>The Journal of nutrition</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pschierer, Volkhard</au><au>Richter, Werner O.</au><au>Schwandt, Peter</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Primary Chylomicronemia in Patients with Severe Familial Hypertriglyceridemia Responds to Long-Term Treatment with (n-3) Fatty Acids</atitle><jtitle>The Journal of nutrition</jtitle><addtitle>J Nutr</addtitle><date>1995-06-01</date><risdate>1995</risdate><volume>125</volume><issue>6</issue><spage>1490</spage><epage>1494</epage><pages>1490-1494</pages><issn>0022-3166</issn><eissn>1541-6100</eissn><coden>JONUAI</coden><abstract>Because it disturbs microcirculation, chylomicronemia can cause severe clinical complications such as acute pancreatitis. Dietary measures are very important in the prevention and treatment of this condition. Dietary supplementation with (n-3) fatty acids has been shown to be of benefit in short-term treatment of chylomicronemia. To evaluate the long-term efficacy of (n-3) fatty acids we added 2.16 or 4.32 g/d (for 3 mo) and 3.24 g/d (for a further 8 mo after 1 mo of no treatment (n-3) fatty acids to the diet of eight patients with primary chylomicronemia. Serum triglycerides decreased significantly from 15.0 ± 2.5 to 9.9 ± 2.8 mmol/L (P < 0.01) after 11 mo of treatment, and VLDL triglycerides decreased from 12.3 ± 2.8 to 9.0 ± 2.4 mmol/L (P < 0.01), resulting in a significant decrease of plasma viscosity from 1.56 ± 0.17 mPa·s to 1.47 ± 0.12 mPa·s (P < 0.01). Total cholesterol, HDL and LDL cholesterol as well as lipoprotein (a) and fibrinogen concentrations were not affected by fish oil treatment. The presence of chylomicrons and chylomicron remnants (apolipoprotein B 48 concentration in the lipoprotein fraction with a density lower than 1.006 kg/L) was significantly reduced from 4.82 ± 1.08 to 1.06 ± 0.38 mg/L (P < 0.01). Body weight increased significantly from 71.0 ± 4.6 kg to 75.2 ± 5.3 kg after 11 mo of treatment with (n-3) fatty acids. These data indicate that despite an increase in body weight, long-term supplementation of a diet with (n-3) fatty acids results in a persistent decrease of serum triglyceride concentrations, a pronounced reduction in the number of chylomicrons present in the fasting state, and an improvement in plasma viscosity.</abstract><cop>Bethesda, MD</cop><pub>Elsevier Inc</pub><pmid>7782902</pmid><doi>10.1093/jn/125.6.1490</doi><tpages>5</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0022-3166 |
ispartof | The Journal of nutrition, 1995-06, Vol.125 (6), p.1490-1494 |
issn | 0022-3166 1541-6100 |
language | eng |
recordid | cdi_proquest_miscellaneous_77339927 |
source | MEDLINE; Alma/SFX Local Collection |
subjects | (n-3) fatty acids Adult Aged Biological and medical sciences Body Weight - drug effects Body Weight - physiology Cholesterol - blood Chylomicrons - blood Diet Dose-Response Relationship, Drug Errors of metabolism Fatty Acids, Omega-3 - administration & dosage Fatty Acids, Omega-3 - pharmacology Fatty Acids, Omega-3 - therapeutic use Female Fibrinogen - analysis Food, Fortified General and cellular metabolism. Vitamins Humans Hyperlipoproteinemia Type IV - blood Hyperlipoproteinemia Type IV - drug therapy hypertriglyceridemia Lipids (lysosomal enzyme disorders, storage diseases) Lipids - blood Lipoproteins - blood Male Medical disorders Medical sciences Metabolic diseases Middle Aged Oils & fats Pharmacology. Drug treatments plasma viscosity primary chylomicronemia Triglycerides - blood |
title | Primary Chylomicronemia in Patients with Severe Familial Hypertriglyceridemia Responds to Long-Term Treatment with (n-3) Fatty Acids |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T01%3A10%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Primary%20Chylomicronemia%20in%20Patients%20with%20Severe%20Familial%20Hypertriglyceridemia%20Responds%20to%20Long-Term%20Treatment%20with%20(n-3)%20Fatty%20Acids&rft.jtitle=The%20Journal%20of%20nutrition&rft.au=Pschierer,%20Volkhard&rft.date=1995-06-01&rft.volume=125&rft.issue=6&rft.spage=1490&rft.epage=1494&rft.pages=1490-1494&rft.issn=0022-3166&rft.eissn=1541-6100&rft.coden=JONUAI&rft_id=info:doi/10.1093/jn/125.6.1490&rft_dat=%3Cproquest_pubme%3E1866389%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=197432960&rft_id=info:pmid/7782902&rft_els_id=S0022316623035617&rfr_iscdi=true |